<DOC>
	<DOC>NCT02177318</DOC>
	<brief_summary>To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 Î¼g) in patients with chronic obstructive pulmonary disease in daily clinical settings</brief_summary>
	<brief_title>Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients with COPD There is no exclusion criterion, because this post marketing study (PMS) is observational survey under condition of normal clinical practice</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>